-
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
Fürstenau, M., Thus, Y. J., Robrecht, S., Mellink, C. H. M., van der Kevie-Kersemaekers, A. M., Dubois, J., von Tresckow, J., Patz, M., Gregor, M., Thornton, P., Staber, P. B., Tadmor, T., Levin, M. D., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Janssens, A., Christiansen, I., & 27 others , 3 Aug 2023, In: Blood. 142, 5, p. 446-459 14 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110
Hengeveld, P. J., Ertem, Y. E., Dubois, J. M. N., Mellink, C. H. M., van der Kevie-Kersemaekers, A-M., Evers, L. M., Heezen, K., Kolijn, P. M., Mook, O. R. F., Motazacker, M. M., Nasserinejad, K., Kersting, S., Westerweel, P. E., Niemann, C. U., Kater, A. P., Langerak, A. W. & Levin, M-D., 1 Jul 2022, In: Leukemia. 36, 7, p. 1935-1938 4 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications